Tech Transfer Day
Living
Therapeutics
SAARBRÜCKEN GERMANY
November 19, 2025
Speaker
Join Us for an Exclusive Event on Living Therapeutics!
Explore the future of medicine at our upcoming Tech Transfer Day Living Therapeutics: where science meets industry to shape tomorrow’s therapies. Hear from two leading industry speakers and dive into key discussions during our expert-led roundtables:
- Navigating Regulatory and Market Pathways
- Translating Living Therapeutics into Scalable Solutions
Whether you are a researcher, entrepreneur, or policymaker, this is your opportunity to connect, collaborate, and contribute to the future of living medicines.
Don’t miss it – register now and be part of the conversation that’s redefining healthcare!
Register
Program
Wednesday, November 19
Welcome
GMOs for health: the Acto story
Dr. Lothar Steidler, Co-founder, Concept and Platform Inventor and Head of Technology of ActoGeniX, later ActoBio Therapeutics and Co-founder of, and partner in Swartberg Experts
Roundtable I
Navigating regulatory and market pathways
Max G. Ostermeier,
Implandata GmbH (DE)
COFFEE BREAK
Enabling Technologies for Precise Engineering of Probiotics & Starter Cultures: How to
Cover the Full Range from nonGMO to GMO
Dr. Claudia Borgmeier, Brain Biotech
Project manager strain development
Roundtable II
Translating Living Therapeutics into scalable solutions
Prof. Dr. Avi Schröder, Technicon – Israel Institute of Technology
LUNCH
Meet the scientists & get to know the projects of the Leibniz Science Campus Living Therapeutic Materials
END
Speaker info
Dr. Claudia Borgmeier
Dr. Claudia Borgmeier is a scientific project manager at BRAIN’s strain development Unit. Her work is focused on supporting industrial collaboration partners who are looking for new and/or improved probiotics and fermented food applications. At the core of her strain development work is the development and application of microbiological and genetic engineering tools as well as the provision of novel strains while integrating all necessary additional technology platforms available at BRAIN.
Dr. Lothar Steidler
Dr. Lothar Steidler is the co-founder, concept inventor, and Head of Technology at ActoGeniX, later ActoBio Therapeutics, and co-founder and partner at Swartberg Experts. He pioneered the use of live GMO Lactococcus strains for local delivery of therapeutic proteins, designing the strain used in the first human study of its kind. He developed a synthetic biology platform for high-throughput construction of clinical-grade strains and led their scale-up to industry-standard manufacturing. His work enabled four ICH-compliant clinical studies targeting inflammatory and autoimmune diseases.
Discussion Moderators
Dr. Shrikrishnan Sankaran
Dr. Shrikrishnan Sankaran is head of the Bioprogrammable Materials group at the Leibniz Institute for New Materials. His team genetically programs probiotic bacteria to sense external stimuli and regulate the production of therapeutic biomolecules in response.
Prof. Dr. Avi Schröder
Prof. Avi Schröder is Associate Professor of Chemical Engineering, Technion–Israel Institute of Technology. His team focuses on nanoscale drug delivery systems for treating metastatic cancer and neurodegenerative diseases, with vast pre-clinical and clinical experience.
Max G. Ostermeier
Max G. Ostermeier is Co-Founder and General Manager of Implandata Ophthalmic Products GmbH (Germany). He drives innovation in ophthalmic surgical products by supporting commercial development of technologically advanced products in cooperation with research institutions, by building operational capabilities for aggressively growing companies, and by creating business and attracting potential acquirers in the global market.